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ABSTRACT 
Non-alcoholic fatty liver disease (NAFLD) is now recognised as the most common cause of 
liver dysfunction worldwide. However, whilst the majority of individuals who exhibit features 
of the metabolic syndrome including obesity and insulin resistance will develop steatosis, 
only a minority progress to steatohepatitis, fibrosis and cirrhosis. Subtle inter-patient genetic 
variations and environment interact to determine disease phenotype and influence 
progression. A decade after the sequencing of the human genome, the comprehensive study 
of genomic variation offers new insights into the modifier genes, pathogenic mechanisms 
and is beginning to suggest novel therapeutic targets. We review the current status of the 
field with particular focus on advances from recent genome-wide association studies.  
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1. INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of liver disease 
encompassing simple fatty infiltration of the liver parenchyma (steatosis), fat and 
inflammation (non-alcoholic steatohepatitis; NASH) and cirrhosis, in the absence of 
excessive alcohol consumption (typically a threshold of <20g/day for women and <30g/day 
for men is adopted)[1, 2].. Population studies show that NAFLD is strongly associated with 
obesity, insulin resistance/type II diabetes mellitus and dyslipidaemia and it is considered by 
many to be the hepatic manifestation of the metabolic syndrome[3-5]. It is now recognised 
that NAFLD is the most common cause of liver dysfunction in developed countries[1]. 
Estimates vary between populations however one large European study found NAFLD 
present in 94% of obese patients (BMI >30 kg/m2), 67% of overweight patients (BMI >25 
kg/m2), and 25% of normal weight patients[6]. The overall prevalence of NAFLD in type 2 
diabetics ranges from 40-70%[6]. As only a minority of patients with NAFLD progress to 
more advanced disease characterised by inflammation, fibrosis, cirrhosis and hepatocellular 
carcinoma (HCC), NAFLD is best considered a complex disease trait where subtle inter-
patient genetic variations and environment interact to determine disease phenotype and 
progression[7, 8]. Here we will review the current understanding of genetic modifiers of 
NAFLD/NASH with particular focus on data from human studies (Figure 1).  
 
2. PATHOGENESIS 
Our current understanding of disease pathogenesis has been achieved through clinic based 
research and the translational study of specific animal models[9, 10]. The initiating events in 
NAFLD/NASH relate to the development of obesity and insulin resistance. Together, these 
promote hepatic free fatty acid (FFA) flux which provides the appropriate milieu for 
NAFLD/NASH to develop. Importantly, the visible steatosis that has for some time been 
considered the ‘first hit’ in the pathogenesis of NAFLD/NASH is now recognised by many 
investigators to be an epiphenomenon reflecting these changes in hepatocyte FFA flux and 
associated cellular stress responses. Recognition of this means that steatosis should now be 
considered an early adaptive response to hepatocyte stress through which potentially 
lipotoxic FFAs are partitioned into relatively stable intracellular triglyceride stores. This was 
elegantly demonstrated by silencing of hepatic DGAT2 expression, a key enzyme mediating 
the conversion of FFA to triglyceride[11]. Rather than ameliorating steatohepatitis, the 
consequent reduction in hepatocyte triglyceride synthesis was associated with a greater 
level of fatty acid oxidation, particularly through Cyp2E1, leading to greater oxidative stress, 
cellular damage and higher serum transaminase levels[11]. Discussion of pathogenesis and 
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the genetic modifiers of progressive NAFLD should now consider the combined effects of 
several fundamental biochemical and immunological mechanisms of liver injury rather than 
adhering to a sequential ‘two-hit’ paradigm. These effects include: (1) Direct hepatocyte 
lipotoxicity; (2) Hepatocellular oxidative stress secondary to free radicals produced during β- 
and ω-FFA oxidation; (3) Endotoxin/TLR4 induced Kupffer cell cytokine release; (4) Cytokine 
release; and (5) Endoplasmic reticulum (ER) stress. Consequent cellular damage triggers a 
mixture of immune mediated hepatocellular injury and both necrotic and apoptotic cell death 
pathways[12-14]. If these persist for some time, these processes lead to stellate cell 
activation, collagen deposition and hepatic fibrosis[15]. In depth discussion of these 
mechanisms falls outside the scope of this review, however this framework will be adopted in 
our discussion of genetic modifiers.  
 
3. TECHNIQUES FOR INVESTIGATING THE GENETIC BASIS OF NAFLD/NASH 
Until recently, the primary approach to the genetic study of complex disease traits was 
through case-control disease-association studies in man where candidate genes were 
selected on the basis of a putative role of their encoded proteins in disease pathogenesis. 
Being reliant on an a priori hypotheses for gene selection, these studies were limited to 
known candidates and therefore were not able to explore the potential role of other less 
obvious genes that may have an equal or greater influence on disease susceptibility.  
In the ten years since the publication of the draft human genome there have been significant 
advances in our understanding of genomic variation. Several million single nucleotide 
polymorphisms (SNPs) have been described across individuals from diverse ethnic 
backgrounds[16-18]. This has paved the way for the development of SNP genotyping arrays 
and genome-wide association studies (GWAS) that have allowed the majority of common 
(minor allele frequency >5%) variability in the human genome to be simultaneously 
surveyed. The availability of high throughput next-generation sequencing offers the prospect 
of even more comprehensive characterisation of genomic variability, particularly the more 
rare genetic variants that are not effectively identified by GWAS but which may have a 
relatively large effect on disease risk. Greater discussion of these techniques falls outside 
the scope of this review but they are discussed more fully elsewhere [19-21].  
The utility of the GWAS approach was demonstrated by one of the earliest reports 
describing simultaneous study of seven different complex diseases[22]. Since then, the 
number of GWAS studies in the literature has expanded exponentially. Amongst these, 
several liver-related diseases and traits have been studied. Factors that influence variation in 
biochemical liver function tests[23], drug induced liver injury[24, 25], gallstone disease[26], 
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primary biliary cirrhosis[27-29], NAFLD[30-32], hepatitis B persistence[33] and hepatitis C 
treatment response[34, 35] have been identified. A welcome consequence of wider adoption 
of non-hypothesis driven GWAS techniques is that the loci identified are frequently novel and 
would not previously have been implicated in disease pathogenesis. However, as often 
neither biological function nor pathogenic mechanisms are known, such associations require 
further detailed study both to determine activity and to validate causality. In addition, 
candidate gene association studies have examined modifiers of disease progression and 
fibrosis[36, 37]. 
 
4. GENOME WIDE ASSOCIATION STUDIES IN NAFLD/NASH RESEARCH 
To date, three GWAS scale studies have been reported in this field[30-32]. Each has 
captured new data and provided additional insights into the role of genomic variation in 
NASH pathogenesis (Table 1).  
4.1. The First GWAS – Romeo et al  
The first NASH related GWAS was a genome-wide survey of non-synonymous sequence 
variation encompassing 9229 SNPs across a mixed population of Hispanic, African 
American and European ancestry derived from the Dallas Heart Study[30, 38]. Although not 
based on direct assessment of steatosis in liver biopsy samples, the non-invasive proton 
magnetic resonance spectroscopy (1H-MRS) technique used to assess hepatic steatosis is 
widely adopted in both human and murine studies[39, 40]. The striking results of this study 
clearly identified the patatin-like phospholipase domain-containing 3 gene (PNPLA3), also 
known as adiponutrin, as a strong modifier of NASH pathogenesis. The study demonstrated 
that the PNPLA3 I148M variant, induced by a cytosine to guanine nucleotide transversion 
mutation (SNP rs738409) which results in an isoleucine to methionine amino acid change at 
codon 148, was associated with increased hepatic fat burden (p=5.9x10-10)[30]. The variant 
allele was most common in Hispanics (minor allele frequency 0.49), which is the group most 
susceptible to NAFLD and where carriage was also found to be associated with increased 
ALT and AST levels. Minor allele frequency was lower in people of European descent (0.23) 
and lowest in African-Americans (0.17), the group found to have the lowest levels of hepatic 
triglyceride accumulation. Furthermore, a gene dosage effect was observed with 
heterozygote carriage of the I148M minor allele conferring increased hepatic triglyceride 
content over wild-type and homozygotes having even greater levels (2-fold more than non-
carriers). The same study also reported a second sequence variation in PNPLA3 
(rs6006460) causing a serine to isoleucine change in codon 453 (S453I). In contrast to the 
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I148M variation, S453I had the opposite ethnic distribution and was associated with reduced 
hepatic triglyceride levels[30, 41]. Together, these two variants were able to account for 72% 
of the ethnic variation in steatosis observed in the study population. 
4.2. The Second GWAS – Chalasani et al 
A second NAFLD GWAS, which was not limited to non-synonymous genetic variation, has 
recently been reported[31]. This used a relatively small all-female cohort of 236 biopsy-
confirmed NAFLD patients and involved genotyping for 325,000 SNPs. Following adjustment 
for age, BMI, diabetes, waist:hip ratio and HbA1c levels in multivariate analysis, an 
association was identified between severity of histological NAFLD activity score and SNP 
rs2645424 on chromosome 8 in the gene encoding farnesyl diphosphate farnesyl 
transferase 1 (FDFT1) (p=6.8x10-7), an enzyme with a role in cholesterol biosynthesis. Other 
associations with fibrosis (chromosome 7, rs343062; p=2.7x10-8) and lobular inflammation 
were seen (including a SNP in the collagen gene COL13A1 (p=2.0x10-7)). In addition loci 
associated with raise ALT were also identified. No associations with steatosis, ballooning 
degeneration or portal inflammation were identified and it is perhaps surprising that no 
association for any feature of NAFLD with PNPLA3 was seen in this study. Whilst the 
associations detected in this study are potentially interesting, they remain to be 
independently replicated in larger patient cohorts. A recent study in a UK cohort of 340 
NAFLD patients failed to find any association for the FDFT1 rs2645424 SNP with severity of 
either fibrosis or steatosis[42].  
4.3. The Third GWAS – Speliotes et al 
The most recent large-scale study of genetic variation in NAFLD adopted a two-stage 
approach[32]. In a first exploratory stage, computerised tomography (CT) measurement of 
hepatic steatosis was examined in a meta-analysis of GWAS data across individuals drawn 
from several large population studies (Age/Gene/Environment Susceptibility-Reykjavik 
Study, Old Order Amish Study, Family Heart Study and Framingham Heart Study). 
Genotypes for 2.4 million SNPs in over 7,100 individuals were available. SNPs from 45 loci 
associated with hepatic lipid content (p<10-3) were identified and association validity tested 
using a cohort of 592 patients with biopsy proven NASH derived from the NIH NASH CRN 
cohort. Five SNPs associated with aspects of the NAFLD phenotype in or near the genes 
PNPLA3 (rs738408), neurocan (NCAN; rs2228603), protein phosphatase 1, regulatory 
(inhibitor) subunit 3B (PPP1R3B; rs4240624), glucokinase regulator (GCKR; rs780094) and 
lysophospholipase-like 1 (LYPLAL1; rs12137855) were identified. The rs738408 PNPLA3 
SNP is in strong linkage disequilibrium with the rs738409 SNP previously identified[30]. 
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PNPLA3, NCAN and PPP1R3B were most strongly associated with CT measured steatosis 
at p<5x10-8 in the initial study. This was also confirmed in the histology validation study for 
PNPLA3 and NCAN but not PPP1R3B. Two additional SNPs in or near GCKR and LYPLAL1 
were shown to be associated with histological steatosis. NCAN, GCKR, LYPLAL1 and 
PNPLA3 were associated with histologically assessed lobular inflammation and/or fibrosis. In 
addition, variants in or near NCAN, GCKR and PPP1R3B were associated with altered 
serum lipid levels and variants near GCKR and PPP1R3B affected glycemic traits. This large 
study confirmed the strong association for PNPLA3 rs738408 with steatosis shown in the 
first GWAS study (section 4.1) and by candidate gene association studies (see 5.2.1 below). 
The other associations are novel though not as strong as for PNPLA3. LYPLAL1 codes for a 
protein with a complementary function to the PNPLA3 gene product in triglyceride 
breakdown so the observed association is biologically plausible. The NCAN gene product 
may have a role in cell adhesion whereas GCKR codes for a regulator of glucose 
metabolism and both are therefore interesting genes in terms of NAFLD susceptibility though 
further studies are needed to identify the precise causative SNPs and the underlying 
mechanisms affecting disease severity.  
 
5. GENETIC MODIFIERS OF NAFLD PATHOGENESIS & PROGRESSION 
5.1. Genetic Modifiers of Metabolic Syndrome Risk 
When considering genetic modifiers of NAFLD one should first consider those genes that 
influence aetiological factors causally linked to the disease. These are exemplified by the 
associated conditions of insulin resistance and obesity for NAFLD. Rather than being simple 
environmental challenges, these factors are themselves, at least in part, genetically 
determined.  
5.1.1. Obesity 
In terms of obesity related genes[43], initial candidate studies were based on discoveries 
from mutant mouse models and focussed on genes related to leptin signalling which links 
obesity with NAFLD[9, 44, 45], however the effect of these genes has proved to be 
uncommon in human disease[46]. Identification of the FTO gene by GWAS analysis of a 
cohort of obese patients has provided a new candidate[47]. Translational validation by 
several groups using targeted and random mutagenesis techniques has provided exciting 
insights into pathogenic mechanisms, however no direct association with fatty liver has yet 
been described[48, 49]. The role of epigenetic imprinting as an influence on obesity and fatty 
liver phenotypes has also been explored in models of NAFLD[50].  
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5.1.2. Insulin Resistance 
The relationship between insulin resistance and progression of NAFLD is complex. Whilst 
multiple loci from GWAS have been associated with type 2 diabetes and insulin 
resistance[51], few have so far carried through to NAFLD. To date, the polymorphisms in 
ENPP1/PC-1 (ectoenzyme nucleotide pyrophosphate phosphodiesterase 1), and IRS-1 
(insulin receptor substrate-1) have been studied in candidate gene studies. A large study 
involving 702 pooled biopsy-proven NAFLD cases from Italy and the UK found that the SNPs 
in both ENPP1 (K121Q) and IRS-1 (Q972R) were independently associated with fibrosis 
scores >1 and insulin resistance[52]. However, a second smaller and arguably 
underpowered study on ENPP1 did not find a significant effect on fibrosis[53]. 
The adiponectin gene may also be relevant to insulin resistance and the metabolic syndrome 
more generally and has been well studied in relation to type 2 diabetes. A study of 119 
patients with NAFLD showed that homozygosity for the variant form of a SNP at position 45 
of exon 2 of this gene was a risk factor for severe fibrosis but not for NASH[54]. A more 
recent large Finnish study with two separate validation cohorts examined the association of 
polymorphisms within adiponectin receptors 1 and 2 (ADIPOR1 and ADIPOR2) as well as 
three peroxisome proliferator activated receptors (PPARA, PPARD and PPARG) with 1H-
MRS measured steatosis and concluded that only the ADIPOR2 SNP (rs767870) was 
associated with hepatic fat accumulation[55]. In a Chinese population, an association with 
the C161T PPARG SNP, reduced plasma adiponectin levels and NAFLD has been 
described. No association was found with the Gly482Ser SNP in the related protein 
PPARGC1A[56].  
 
5.2. Genetic Modifiers of Hepatic Fatty Acid Flux and Triglyceride Levels 
Steatosis occurs when the rate of import or synthesis of fatty acids by hepatocytes exceeds 
the rate of export or catabolism[57, 58]. Given the recent evidence that esterification of FFA 
to triglyceride is a protective mechanism which limits hepatocellular exposure to FFA 
induced lipotoxicity[11], polymorphisms in genes that mediate synthesis, storage and export 
of triglyceride are likely candidate modifiers for NASH severity and progression. The majority 
of NAFLD associated genes so far identified are from traditional candidate gene allele-
association studies based on existing understanding of hepatocyte lipid handling.  
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5.2.1. Patatin-like phospholipase domain-containing 3 (PNPLA3)  
As already discussed, interest in the role of PNPLA3 in the pathogenesis of NASH started 
with its identification as a genetic modifier of steatosis risk in a GWAS study. Later the same 
year a GWAS seeking factors that influence variation of common clinical chemistry indices 
reported that the I148M allele was one of two loci associated with raised serum ALT levels in 
populations of European and Indian-Asian descent (chromosome 10: APN1-ERLIN1-CHUK 
and chromosome 2: PNPLA3-SAMM50)[23]. The association of PNPLA3 with NAFLD/NASH 
has been independently replicated in both adult[59-62] and paediatric[62-65] cohorts, as has 
its association with raised ALT/AST levels[66] (Table 2). There is also evidence from biopsy 
based studies that carriers of the I148M variant exhibit more severe steatohepatitis with 
greater levels of fibrosis[60, 62]. Illustrating the convergence in our understanding of the 
pathogenesis of alcoholic liver disease and NAFLD, studies in alcohol dependent patients 
have linked advanced fibrosis or cirrhosis with carriage of the I148M allele[67]. This has 
been independently validated in two additional European cohorts[68, 69]. Further, there is 
evidence that PNPLA3 influences steatosis, fibrosis and risk of developing HCC in patients 
with chronic hepatitis C infection[70].  
The PNPLA3 gene on chromosome 22 encodes a 481 amino acid protein that is closely 
related to adipose triglyceride lipase (ATGL/PNPLA2), the major triglyceride hydrolase in 
adipose tissue[41, 71]. PNPLA3 has been primarily associated with severity of hepatic lipid 
accumulation however its precise physiological role in vivo remains incompletely 
characterised[41]. Current evidence would suggest that the influence of PNPLA3 on hepatic 
steatosis is not through affecting insulin resistance as assessed by hyperinsulinaemic, 
euglycaemic clamp[59, 61] and plasma insulin response to oral glucose tolerance 
testing[72]; or with the broader features of the metabolic syndrome such as BMI, 
dyslipidaemia and overt type 2 diabetes mellitus[73]. Rather, consistent with the concept of 
NASH as a complex disease trait, the evidence suggests that PNPLA3 variation sensitises 
the liver to environmental stressors. Thus, in European cohorts I148M carriage was only 
found to associate with elevations of AST/ALT in the presence of obesity[72].  
The challenge remains to better understand the role of PNPLA3 and hence the mechanisms 
through which the I148M variant exhibits its metabolic effects. Studies have to some extent 
been hampered by inter-species differences in gene expression pattern. In man PNPLA3 is 
found in adipose tissue but is most strongly expressed in the liver[74, 75], whilst in normal 
mice gene expression is at low levels in liver tissue but is abundant in white and brown 
adipose tissue[76, 77]. In both species hepatic expression is increased after feeding and is 
also raised in obese humans[59] and in Ob mice[77] whilst fasting reduces PNPLA3 
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expression [41, 77]. Recent in vitro studies with recombinant adiponutrin expressed in HUH-
7 cells have shown that this enzyme can hydrolyze emulsified triglyceride and that the I148M 
polymorphism is associated with substantially reduced enzymatic activity[78]. Structural 
analysis of PNPLA3 indicates that the I148M mutation does not directly alter the enzyme’s 
highly conserved S47/D166 catalytic dyad. Instead, the I148M amino acid change lies within 
the hydrophobic substrate-binding groove and prevents substrate access to the active 
site[78]. Mechanistic studies demonstrate that postprandial PNPLA3 expression is controlled 
by an insulin mediated feed-forward loop through the LXR/RXR heterodimer and the 
transcription factor SREBP-1c[74]. These effects are responsive to post-translational control 
by the types of fatty acids present[74]. Specifically, selected saturated (palmitate, C16:0), 
monounsaturated (oleate, C18:1) and polyunsaturated fatty acids (linoleic acid, C18:2) led to 
increased PNPLA3 protein expression whilst very long chain fatty acids (arachadonic acid, 
C20:4 and eicosapentanoic acid, C20:5) did not effect PNPLA3 expression[74]. It has also 
been suggested that, in addition to lipolytic activity, PNPLA3 may also exhibits lipogenic 
transacetylase activity although this has not been uniformly replicated[78, 79]. These 
apparent mixed enzymatic actions, coupled with the transcriptional regulation of PNPLA3 by 
feeding and the specific fatty acid profile present suggests that the action of PNPLA3 could 
vary according tissue and metabolic milieu. Whilst partially purified PNPLA3 can catalyse 
triglyceride hydrolysis in vitro, expression patterns and regulation have led some 
investigators to suggest that the enzyme may be primarily involved in lipid remodelling rather 
than catabolism[74].  
5.2.2. Microsomal Triglyceride Transfer Protein (MTTP)  
Microsomal Triglyceride Transfer Protein (MTTP) mediates the synthesis and secretion of 
very-low density lipoprotein in the liver and intestine. A loss of function frame-shift mutation 
in MTTP causes abetalipoproteinemia (OMIM #200100) however, whilst this is associated 
with marked hepatocyte triglyceride accumulation, it is much less frequently associated with 
progressive steatohepatitis or fibrosis[80]. A guanine to thiamine transversion at position -
493 in the promoter region has been associated with reduced gene transcription, lower 
MTTP levels and hepatocyte failure of triglyceride excretion. Evidence has been presented 
that NAFLD patients homozygous for the low-activity G allele have increased steatosis and 
higher histological NASH grade compared to heterozygous patients or patients homozygous 
for the high-activity T allele[81, 82]. Unfortunately, these data should be interpreted with 
caution as histological data on NASH activity was only available on a small cohort of 63 
patients[81] and a recent larger study of 131 biopsy proven NAFLD cases from Brazil failed 
to show a significant effect for the same polymorphism[83].  
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5.2.3. Phosphatidylethanolamine methyltransferase (PEMT) 
Phosphatidylethanolamine methyltransferase (PEMT) catalyses de novo synthesis of 
phosphatidylcholine which is needed for very-low-density lipoprotein synthesis. Two studies 
have reported an association between NAFLD and a non-synonymous PEMT exon 8 
guanine-to-adenine transversion. The larger study included 107 biopsy-proven NASH 
patients from Japan and demonstrated that the consequent loss-of-function V175M amino 
acid change was more common in NASH patients compared to controls[84]. Further, V175M 
positive NASH patients tended to have lower BMI, suggesting they were genetically 
predisposed to develop NASH. A second biopsy-based American study also suggested that 
V175M was more common among NASH cases compared to controls[85].  
5.2.4. Apolipoprotein C3 (ApoC3) 
An association with degree of hepatic steatosis and two SNPs, rs2854116 (T-455C) and 
rs2854117 (C-482T), located within the promoter region of Apolipoprotein C3 (ApoC3) has 
been reported in cohorts of Asian-Indian and non-Asian ethnicity[86]. Both SNPs cause 
increased ApoC3 expression and were already recognised as mediators of postprandial 
hypertriglyceridaemia in humans and murine studies via inhibition of lipoprotein lipase 
activity. It has been suggested that the increased circulating chylomicron-remnant load was 
preferentially taken up by hepatic scavenger receptors leading to steatosis[86]. However, the 
association of these SNPs with steatosis severity was not confirmed in two recent studies. 
The first of these failed to show any association between these SNPs with either hepatic 
triglyceride content or insulin resistance in approximately 2,000 Americans of African, 
European and Hispanic ethnicity[87]. The second, involving 758 biopsy proven NAFLD 
cases of European ethnic origin, failed to show any relationship for these APOC3 SNPs with 
steatosis or fibrosis severity or with NASH[88]).  
 
5.2.5. Transcription Factors & Nuclear Receptors 
Following the observation that mice deficient in the NR1I2/PXR (pregnane X receptor) gene 
develop steatosis[89], a recent study has focussed on its role in lipid homeostasis and 
NAFLD. PXR is a transcription factor with a well established role in regulation of hepatic 
detoxification mechanisms[90]. It may also influence lipid homeostasis through effects on the 
fatty acid translocase gene (CD36) and several lipogenic enzymes[89]. Two SNPs 
(rs7643645 and rs2461823) were found to be significantly associated with aspects of the 
NAFLD phenotype in a group of 188 patients compared with 102 healthy controls and were 
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also a predictor of disease severity[91]. One SNP (rs7643645) is believed to lie within a 
binding site for the transcription factor HNF-4 and so may affect expression of the genes 
such as CYP3A4 and ABCB1. Effects on lipid homeostasis are therefore also possible but 
the findings for NAFLD need to be confirmed independently. SNPs in other genes encoding 
proteins involved in regulating intra-hepatic FFA flux and triglyceride synthesis, storage and 
export are also attractive candidates as NAFLD risk factors. In addition to those described 
above, published candidate gene association studies support a role for several other genes 
including Transcription factor 7-like 2 (TCF7L2)[92], Apolipoprotein E[93, 94] and MRP2 
(ABCC2)[95] in hepatic fat accumulation.  
 
5.3. Genetic Modifiers of Progression to Steatohepatitis 
5.3.1. Genes Influencing Oxidative Stress 
Genetic modifiers of oxidative stress fall into two broad categories, those that encode 
proteins involved in the generation of reactive oxygen species (ROS) or those that mediate 
cellular antioxidant defence. The former group includes genes that are specific to a given 
aetiology, as well as those that may sensitise hepatocytes to oxidative stress damage 
irrespective of aetiology (e.g. HFE). The latter group includes the main mitochondrial ROS 
scavenger manganese-dependent superoxide dismutase (SOD2) and genes that influence 
the relative abundance of anti-oxidant reduced glutathione stores.  
Given that liver iron deposition promotes oxidative stress, the HFE gene is an obvious 
candidate in disease pathogenesis for NAFLD. The evidence of a role for HFE in NAFLD is 
mixed. An initial Australian study demonstrated that 31% of 51 NASH patients carried at 
least one copy of the C282Y HFE mutation compared to only 13% of controls[96]. This is 
supported by a second study in 126 patients with biopsy proven NASH which also reported 
that the C282Y mutation was associated more advanced disease including bridging fibrosis 
or cirrhosis[97]. However, another study of 263 consecutive patients with NAFLD[98], and 
two further small European studies[99, 100], found the prevalence of the C282Y and H63D 
mutations to be identical to the control population.  
In the face of the increased hepatocyte FFA flux encountered in NAFLD, mitochondrial β- 
and extra-mitochondrial β- and ω- fatty acid oxidation are major sources of ROS. An alanine-
to-valine substitution in codon 16 (A16T) of the SOD2 mitochondrial targeting sequence 
increases MnSOD activity which leads to increased generation of peroxide and hence 
cellular damage. This polymorphism has been associated with advanced hepatic fibrosis in 
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NAFLD in both Japanese[81] and European[101] cohorts. The European study used both 
case-control and intra-familial association methodology to report a consistent association 
between this SNP and fibrosis in NAFLD and also demonstrated a gene dosage effect where 
the presence of significant fibrosis increased with the number of valine (T) alleles. In the 
family study, the valine allele was transmitted on 47 of 76 possible occasions (62%), 
whereas the C allele was transmitted on only 29 of 76 occasions (38%; p=0.038) [101]. 
Multivariate analysis using a cohort of more than 500 patients with biopsy proven NASH 
showed susceptibility to advanced fibrotic disease was determined by SOD2 genotype (OR 
1.56 (95%CI 1.09-2.25), p=0.014), PNPLA3 genotype (p=0.041), type 2 diabetes mellitus 
(p=0.009) and histological severity of NASH (p=2.0x10-16)[101]. 
Cellular oxidative stress defence is largely mediated by glutathione which may be 
conjugated to xenobiotics and ROS. Glutamate-cysteine ligase (gamma-glutamylcysteine 
synthetase), composed of two subunits encoded by the genes GCLC and GCLM, is the rate 
limiting step in synthesis of glutathione. Murine studies have demonstrated that absence of 
GCLC causes steatosis and liver failure[26]. A recent study of NAFLD in Brazil involving 131 
patients examined the effects of the C-129T promoter region polymorphism involving the 
GCLC gene and demonstrated that carriers of the mutant allele were overrepresented in a 
steatohepatitis arm compared to those with simple steatosis[83].  
 
5.3.2. Genes Influencing Endotoxin Response & TLR4 
In recent years there has been mounting interest in the role of the gut flora-liver axis in the 
pathogenesis of fatty liver disease with evidence supporting a role for endotoxin-mediated 
cytokine release in the pathogenesis of NAFLD from both human and murine studies. The 
identification of promoter region polymorphisms in genes encoding endotoxin receptors has 
provided investigators with a new set of candidate genes for study. CD14, a 
lipopolysaccharide receptor expressed on monocytes, macrophages and neutrophils 
enhances toll-like receptor-4 (TLR4) endotoxin receptor signalling. Genetic data supporting a 
role for TLR4 polymorphisms rs4986791 and rs4986790 in the pathogenesis of hepatitis C 
related fibrosis in man is available[102, 103]. In addition, a spontaneous null mutation in 
TLR4 present in C3H/J mice has provided a useful tool with which to explore the role of 
TLR4/endotoxin in NAFLD pathogenesis in the laboratory[104]. One preliminary study in 
NAFLD found no association with polymorphisms in either TLR4 or the NOD2 receptor for 
bacterial cell wall peptidoglycan but did reported an association with a cystosine-to-thymine 
polymorphism at position -159 in the 5’ promoter region of CD14[105]. Carriage of the CD14 
minor allele is associated with increased expression of both soluble and membrane bound 
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CD14[106]. Once again, larger studies are required to validate these findings.  
 
5.3.3. Genes Influencing Cytokine Activity 
Investigation of the role of TNFα and other cytokines in NASH was first stimulated by the 
apparent similarity between NASH and the effects of pro-inflammatory cytokines such as 
TNFα[107]. The TNFα guanine-to-adenine promoter polymorphism at position -238 has been 
associated with NASH[108]. In a separate study, DNA from 102 Japanese patients was 
screened for SNPs in TNFα and serum TNF receptor-2 levels assayed. sTNFr-2 levels were 
significantly higher in NASH patients than patients with simple steatosis or healthy controls. 
The carrier frequencies of polymorphisms at -1031C and -863A in the promoter region were 
significantly higher in NASH than steatosis, however no significant difference between those 
with NAFLD and the control population was detected[109]. Whilst interesting, this small 
study requires replication before any firm conclusions on the role of TNFα as a NASH 
susceptibility gene can be made. In a small study of 114 NAFLD cases, including 59 who 
had undergone liver biopsy, an IL-6 promoter region G-174C SNP was found to be more 
common in cases of NASH[53].  
 
5.4. Genetic Modifiers of Fibrogenesis and Disease Progression 
The majority of research into hepatic fibrogenesis has been conducted in chronic hepatitis C 
infected cohorts however, as stellate cell activation and collagen deposition are a final 
common pathway of chronic liver injury, the genes identified remain strong candidates for a 
role in NAFLD-related fibrosis[110]. Candidates suggested by these studies include 
transforming growth factor (TGF)-β1, connective tissue growth factor, matrix 
metalloproteinase 3, PPARα, DDX5, CPT1A and various fibrogenic adipocytokines including 
angiotensin II. One of the few pro-fibrotic polymorphisms independently validated in multiple 
human viral hepatitis studies and in animal models is carriage of the pro-coagulant Factor V 
Leiden mutation (R506Q; OMIM #612309)[37, 111, 112]. Give the evidence that the 
metabolic syndrome is a pro-coagulant state and that fibrosis progression in NAFLD is 
associated with the presence of greater thrombotic risk[113], it is tempting to speculate that 
polymorphisms related to coagulation activation and signalling may also influence 
fibrogenesis[114] however gene association evidence is currently lacking.  
The transcription factor nuclear factor-κB (NF)-κB promotes survival of hepatic 
myofibroblasts and hepatic fibrogenesis. It is recognised that angiotensin II mediates this 
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effect through activation of IκB kinase (IKK) phosphorylation of the NF-κB subunit RelA at 
Ser 536[115]. Five of 12 SNPs studied in the angiotensin II receptor 1 (ATGR1) gene were 
shown to associate with steatohepatitis in a cohort of patients with biopsy proven 
NASH[116]. The strongest association was with SNP rs3772622 (OR=1.95, 95%CI 1.49-
2.55; p=1.2x10-6) with the other four SNPs being found to lie within the same linkage block. 
This SNP was also shown to be significantly associated with degree of hepatic fibrosis[116]. 
Another report indicates that obese patients possessing both the high TGFβ1 and 
angiotensinogen producing SNPs may be more susceptible to advanced fibrosis. However 
this study involved very small patient numbers and is yet to be replicated[117]. These 
findings are consistent with reports that show benefit of angiotensin receptor blockers such 
as losartan in ameliorating fibrosing steatohepatitis both in vitro and in vivo and demonstrate 
how knowledge of the genetic modifiers of disease may inform development of potential 
therapies[115, 118].  
Kruppel-like factor (KLF6) is a ubiquitously expressed transcription factor which was found to 
be expressed by activated stellate cells soon after injury[119]. Evidence suggests that KLF6 
expression is increased in rat models of NASH and regulates expression of several key 
genes that mediate fibrogenesis, making it an attractive candidate modifier of fibrosis 
severity in human NAFLD[120]. A SNP affecting mRNA splicing (rs3750861) has been 
shown to be functionally significant[121]. Carriage of this SNP has been shown to associate 
with more mild hepatic fibrosis in three separate European NAFLD cohorts[36].  
 
6. CONCLUSIONS 
Like the majority of clinically important diseases, NAFLD is a complex disease trait where 
genetic factors and environmental influences combine to determine disease phenotype and 
progression. The relative importance of these factors will vary between populations 
depending on background modifier genes and lifestyle choices/challenges. During the last 
decade the advent of the GWAS and whole-genome sequencing technologies has provided 
investigators with the tools to comprehensively study variability within the human genome. 
The advent of genome-led tailored therapy based on genetic risk assessment in the clinic 
remains some way off. However, our greater understanding of how genetic variation 
modifies disease phenotype offers new insights into the underlying physiological processes 
and pathophysiological mechanisms. With this opportunity comes the challenge of 
translating these findings into tangible therapeutic benefits.  
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TABLE 1: Loci Identified in NAFLD/NASH GWAS Studies 
Study SNP Gene Symbol Gene Name/Location Association 
Romeo, 2008 [30] rs738409 PNPLA3 Patatin-like 
phospholipase domain-
containing 3 
MRI measured 
steatosis 
Chalasani, 2010 
[31] 
rs2645424 FDFT1 Farnesyl diphosphate 
farnesyl transferase 1 
Histological NASH 
activity score 
 rs343062 - Chromosome 7 Histological fibrosis 
 rs1227756 COL13A1 Collagen, type XIII, 
alpha 1 
Histological lobular 
inflammation 
 rs6591182 - Chromosome 11 Histological lobular 
inflammation 
 rs887304 EFCAB4B EF-hand calcium 
binding domain 4B 
Histological lobular 
inflammation 
 rs2499604 - Chromosome 1 Serum ALT 
 rs6487679 PZP Pregnancy zone protein Serum ALT 
 rs14212001 - Chromosome 18 Serum ALT 
 rs2710833 - Chromosome 4 Serum ALT 
Speliotes, 2011 [32] rs738408 PNPLA3 Patatin-like 
phospholipase domain-
containing 3 
CT measured 
steatosis & 
histological NAFLD 
 rs2228603 NCAN Neurocan CT measured 
steatosis & 
histological NAFLD 
 rs4240624 PPP1R3B Protein phosphatase 1, 
regulatory (inhibitor) 
subunit 3B 
CT measured 
steatosis (not 
validated in histology 
cohort) 
 rs780094 GCKR; Glucokinase regulator Histological NAFLD 
 rs12137855 LYPLAL1 Lysophospholipase-like 
1 
Histological NAFLD 
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TABLE 2: Genetic Studies Indicating a Role for PNPLA3 in NAFLD 
Study Study 
Design 
Cohort Studied Associated Phenotype 
Yuan, 2008 [23] GWAS 
(n=12,419) 
Indian-Asian & European ↑ ALT (serum biochemistry only) 
Romeo, 2008 [30] GWAS 
(n=2,111) 
USA based European-
American; African-
American & Hispanic 
↑ 
1
H-MRS Liver TG content;  
↑ ALT/AST in Hispanics 
Kotronen, 2009 
[59] 
Candidate 
Gene 
(n=291) 
Finnish ↑ 
1
H-MRS Liver TG content;  
No association with Insulin 
Resistance 
Sookoian, 2009 
[60] 
Candidate 
Gene 
(n=266) 
Argentinean ↑ Biopsy proven steatosis;  
↑ Risk of histological progression & 
inflammation 
Kantartzis, 2009 
[61] 
Candidate 
Gene 
(n=330) 
German ↑ 
1
H-MRS Liver TG content;  
↑ ALT & ↑ AST 
Romeo, 2010 [72] Candidate 
Gene 
(n=678) 
Italian (BMI>30kg/m
2
) ↑ ALT if Obese 
Kollerits, 2010 [66] Candidate 
Gene 
(n=4,290) 
European ↑ ALT & ↑ AST 
Romeo, 2010 [63] Candidate 
Gene 
(n=475) 
Italian (Obese 
children/adolescents) 
↑ ALT & ↑ AST 
Speliotes, 2010 
[73] 
Candidate 
Gene 
(n=592) 
USA based European-
American 
↑ Risk of histological progression & 
inflammation 
Speliotes, 2011 
[32] 
GWAS Meta-analysis European 
and USA based cohorts 
↑ CT Liver TG content 
↑ Risk of histological progression & 
inflammation 
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Figure 1: Summary of Genetic Modifiers of Progressive NAFLD 
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